<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00462852</url>
  </required_header>
  <id_info>
    <org_study_id>PRH-HCTU-FRAGEM</org_study_id>
    <secondary_id>CDR0000540180</secondary_id>
    <secondary_id>PRH-HCTU-FRAGEM-V-12.1</secondary_id>
    <secondary_id>CTA-MF8000/13558</secondary_id>
    <secondary_id>EU-20721</secondary_id>
    <secondary_id>LILLY-PRH-HCTU-FRAGEM</secondary_id>
    <secondary_id>ISRCTN76464767</secondary_id>
    <nct_id>NCT00462852</nct_id>
  </id_info>
  <brief_title>Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer</brief_title>
  <official_title>A Phase II Randomized Study of Chemo-Anticoagulation (Gemcitabine-Dalteparin) Versus Chemotherapy Alone (Gemcitabine) for Locally Advanced and Metastatic Pancreatic Adenocarcinoma [FRAGEM]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hull University Teaching Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop&#xD;
      the growth of tumor cells, either by killing the cells or by stopping them from dividing.&#xD;
      Anticoagulants, such as dalteparin, may help prevent blood clots from forming in patients&#xD;
      being treated with gemcitabine for pancreatic cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying how well gemcitabine works with or&#xD;
      without dalteparin in treating patients with locally advanced or metastatic pancreatic&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the incidence of venous thromboembolism in patients with locally advanced or&#xD;
           metastatic pancreatic cancer treated with gemcitabine hydrochloride and dalteparin&#xD;
           versus gemcitabine hydrochloride alone.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the survival benefit, in terms of increased (from 70% to 85%) survival at 12&#xD;
           weeks, of patients treated with these regimens.&#xD;
&#xD;
        -  Compare the toxicity of these regimens.&#xD;
&#xD;
        -  Compare the overall survival of patients treated with these regimens.&#xD;
&#xD;
        -  Compare the time to disease progression in patients treated with these regimens.&#xD;
&#xD;
        -  Determine the effect of gemcitabine hydrochloride and dalteparin on serological markers&#xD;
           of thromboangiogenesis.&#xD;
&#xD;
      OUTLINE: This is a multicenter, randomized study. Patients are stratified according to&#xD;
      disease progression (locally advanced vs metastatic) and Karnofsky performance status (≥ 80%&#xD;
      vs &lt; 80%). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive gemcitabine hydrochloride IV over 30 minutes once weekly in&#xD;
           weeks 1-7 and 9-11.&#xD;
&#xD;
        -  Arm II: Patients receive low molecular weight dalteparin subcutaneously once daily in&#xD;
           weeks 1-12. Patients also receive gemcitabine hydrochloride as in arm I.&#xD;
&#xD;
      Blood samples are acquired at baseline for analysis of circulating tissue factor and vascular&#xD;
      endothelial growth factor.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 120 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of venous thromboembolism reduction</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early survival benefit</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disease progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of drug combination on serological markers of thromboangiogenesis</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Thromboembolism</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dalteparin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>diagnostic laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed metastatic or locally advanced&#xD;
             adenocarcinoma of the pancreas&#xD;
&#xD;
               -  Patients with clinical 'high probability' of pancreatic cancer and biopsy&#xD;
                  suggestive but not diagnostic of pancreatic cancer may be eligible based on&#xD;
                  review by the principal investigator&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  No clinical evidence of active venous thromboembolism&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status (PS) 60-100% OR WHO PS 0-2&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 2,000/mm³&#xD;
&#xD;
          -  WBC &gt; 3,000/mm³&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm³&#xD;
&#xD;
          -  Creatinine clearance &gt; 50 mL/min&#xD;
&#xD;
          -  INR ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 times ULN (stent allowed)&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No cerebrovascular accident within the past 6 months&#xD;
&#xD;
          -  No obvious contraindication to anticoagulation, including the following:&#xD;
&#xD;
               -  Bleeding diathesis&#xD;
&#xD;
               -  Active peptic ulcer&#xD;
&#xD;
               -  Ulcerating cancer into duodenum&#xD;
&#xD;
          -  No history of other advanced malignancy&#xD;
&#xD;
          -  No gross hematuria&#xD;
&#xD;
          -  No melaena or gross evidence of gastrointestinal bleeding (other than piles)&#xD;
&#xD;
          -  No requirement for a central line&#xD;
&#xD;
          -  No other significant medial or psychiatric illness that, in the opinion of the&#xD;
             investigator, would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior gemcitabine hydrochloride-containing treatment&#xD;
&#xD;
          -  No other concurrent cytotoxic chemotherapy, immunotherapy, hormonal therapy (excluding&#xD;
             contraceptives and replacement steroids), or experimental medications&#xD;
&#xD;
          -  No other concurrent specific anticancer therapy as a result of disease progression&#xD;
&#xD;
          -  No concurrent caval filter device&#xD;
&#xD;
          -  No other concurrent anticoagulants for venous thromboembolism or other reasons (e.g.,&#xD;
             atrial fibrillation)&#xD;
&#xD;
          -  No concurrent acetylsalicylic acid (&gt; 75 mg) as an antiplatelet drug for a preexisting&#xD;
             cardiovascular condition&#xD;
&#xD;
          -  No concurrent clopidogrel bisulfate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Maraveyas</last_name>
    <role>Study Chair</role>
    <affiliation>Hull University Teaching Hospitals NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Princess Royal Hospital at Hull and East Yorkshire NHS Trust</name>
      <address>
        <city>Hull</city>
        <state>England</state>
        <zip>HU8 9HE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Lancaster Infirmary</name>
      <address>
        <city>Lancaster</city>
        <state>England</state>
        <zip>LA1 4RP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. George's Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maidstone Hospital</name>
      <address>
        <city>Maidstone</city>
        <state>England</state>
        <zip>ME16 9QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital</name>
      <address>
        <city>Nottingham</city>
        <state>England</state>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scarborough General Hospital</name>
      <address>
        <city>Scarborough</city>
        <state>England</state>
        <zip>YO12 6QL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scunthorpe General Hospital</name>
      <address>
        <city>Scunthorpe</city>
        <state>England</state>
        <zip>DN15 7BH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>April 18, 2007</study_first_submitted>
  <study_first_submitted_qc>April 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2007</study_first_posted>
  <last_update_submitted>August 9, 2013</last_update_submitted>
  <last_update_submitted_qc>August 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2013</last_update_posted>
  <keyword>thromboembolism</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>stage II pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

